董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Boris Nikolic | 男 | Director | 48 | 17.00万美元 | 未持股 | 2018-04-27 |
| Jessica Hopfield | 女 | Director | 53 | 未披露 | 未持股 | 2018-04-27 |
| Andrew Hirsch | 男 | Director | 47 | 未披露 | 未持股 | 2018-04-27 |
| James Mullen | 男 | Director and Chairman | 58 | 未披露 | 未持股 | 2018-04-27 |
| Jessica Hopfield | 女 | Director | 53 | 未披露 | 未持股 | 2018-04-27 |
| Akshay K. Vaishnaw | 男 | Director | 55 | 16.31万美元 | 未持股 | 2018-04-27 |
| Andrew Hirsch | 男 | Director | 47 | 24.64万美元 | 未持股 | 2018-04-27 |
| Katrine Bosley | 女 | Director,President and Chief Executive Officer | 50 | 609.15万美元 | 未持股 | 2018-04-27 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Andrew A. F. Hack | 男 | Chief Financial Officer | 44 | 205.15万美元 | 未持股 | 2018-04-27 |
| Charles Albright | 男 | Chief Scientific Officer | 60 | 126.66万美元 | 未持股 | 2018-04-27 |
| Gerald Cox | 男 | Chief Medical Officer | 59 | 246.75万美元 | 未持股 | 2018-04-27 |
| Katrine Bosley | 女 | Director,President and Chief Executive Officer | 50 | 609.15万美元 | 未持股 | 2018-04-27 |
董事简历
中英对照 | 中文 | 英文- Boris Nikolic
-
Boris Nikolic自2015年8月起担任公司董事。Nikolic自2015年2月起担任投资基金bng0 LLC管理合伙人；自2014年4月起担任投资基金Biomatics Capital管理合伙人。他从2009年4月到2014年4月担任bgC3（比尔盖茨的私人办公室）科学与技术首席顾问。Nikolic从2002年到2010年担任Harvard Medical School助理教授。Nikolic持有克罗地亚萨格勒布the Zagreb Medical School硕士学位。他现任BlueTalon, Inc.和 Digisight Technologies, Inc.董事，两家公司都是私人软件公司；Omniome, Inc.（一家私人生物技术公司）董事；之前曾担任Schr dinger, LLC（一家私人化学配方软件公司）董事。
Boris Nikolic, M.D., has served as a member of our board of directors since August 2015. Dr. Nikolic has served as managing partner of investment fund bng0 LLC since February 2015 and has served as Managing Partner of investment fund Biomatics Capital since April 2014. From April 2009 to April 2014 he served as Chief Advisor for Science and Technology to Bill Gates at bgC3 a think tank. From 2002 to 2010 Dr. Nikolic was an assistant professor at Harvard Medical School. Dr. Nikolic earned his M.D. from the Zagreb Medical School in Zagreb, Croatia. He currently serves on the board of directors of Omniome, Inc., a private biotechnology company, and eGenesis, Inc., a private biotechnology company. He previously served on the board of directors of Schrodinger, LLC, a private chemical simulation software company, Digisight Technologies, Inc., a private software company, and BlueTalon, Inc., a private software company. - Boris Nikolic自2015年8月起担任公司董事。Nikolic自2015年2月起担任投资基金bng0 LLC管理合伙人；自2014年4月起担任投资基金Biomatics Capital管理合伙人。他从2009年4月到2014年4月担任bgC3（比尔盖茨的私人办公室）科学与技术首席顾问。Nikolic从2002年到2010年担任Harvard Medical School助理教授。Nikolic持有克罗地亚萨格勒布the Zagreb Medical School硕士学位。他现任BlueTalon, Inc.和 Digisight Technologies, Inc.董事，两家公司都是私人软件公司；Omniome, Inc.（一家私人生物技术公司）董事；之前曾担任Schr dinger, LLC（一家私人化学配方软件公司）董事。
- Boris Nikolic, M.D., has served as a member of our board of directors since August 2015. Dr. Nikolic has served as managing partner of investment fund bng0 LLC since February 2015 and has served as Managing Partner of investment fund Biomatics Capital since April 2014. From April 2009 to April 2014 he served as Chief Advisor for Science and Technology to Bill Gates at bgC3 a think tank. From 2002 to 2010 Dr. Nikolic was an assistant professor at Harvard Medical School. Dr. Nikolic earned his M.D. from the Zagreb Medical School in Zagreb, Croatia. He currently serves on the board of directors of Omniome, Inc., a private biotechnology company, and eGenesis, Inc., a private biotechnology company. He previously served on the board of directors of Schrodinger, LLC, a private chemical simulation software company, Digisight Technologies, Inc., a private software company, and BlueTalon, Inc., a private software company.
- Jessica Hopfield
-
Jessica Hopfield，自2015年7月起担任董事；2015年10月被任命为the Joslin Diabetes Center的理事长，也是 rEVO Biologics的独立董事；2013年至2015年10月间担任the Joslin Diabetes Center的副理事长。她是一名杰出的医疗保健行业高管和糖尿病专家，在医疗保健行业有超过20年的丰富经验。她是初创医疗保健公司（寻求创新知识产权的商业化途径）的战略顾问和投资商。1995年至2009年，她担任了McKinsey & Company的合伙人，涉及其全球制药和医疗器械事务，在制药、生物技术、医疗器械和定制行业服务客户，专注于战略、研发管理和营销。她也曾担任过Merck Sharp & Dohme Corp.的临床开发、结果研究及营销的管理职位。她获得了Yale College的学士学位，Harvard Graduate School of Business Administration的工商管理硕士学位，是一名Baker学者，以及The Rockefeller University的神经系统科学/生物化学博士学位。
Jessica Hopfield,has served on Board of Directors since July 2015, serving as Lead Independent Director from August 2016 through December 2018. She is the former Chair of the Joslin Diabetes Center.She is a strategic advisor and investor in healthcare and technology firms seeking to commercialize innovative intellectual property. From 1995 to 2009, Dr. Hopfield was a Partner at McKinsey & Company in their global pharmaceuticals and medical devices practice and she served clients across the pharmaceutical, biotech, medical device and consumer industries with a focus on strategy, R&D management and marketing. She also previously held management positions at Merck Sharp & Dohme Corp. in clinical development, outcomes research, and marketing. Dr. Hopfield earned a Bachelor of Science from Yale College, an MBA from the Harvard Graduate School of Business Administration as a Baker Scholar, and a Doctor of Philosophy in Neuroscience/Biochemistry from The Rockefeller University. - Jessica Hopfield，自2015年7月起担任董事；2015年10月被任命为the Joslin Diabetes Center的理事长，也是 rEVO Biologics的独立董事；2013年至2015年10月间担任the Joslin Diabetes Center的副理事长。她是一名杰出的医疗保健行业高管和糖尿病专家，在医疗保健行业有超过20年的丰富经验。她是初创医疗保健公司（寻求创新知识产权的商业化途径）的战略顾问和投资商。1995年至2009年，她担任了McKinsey & Company的合伙人，涉及其全球制药和医疗器械事务，在制药、生物技术、医疗器械和定制行业服务客户，专注于战略、研发管理和营销。她也曾担任过Merck Sharp & Dohme Corp.的临床开发、结果研究及营销的管理职位。她获得了Yale College的学士学位，Harvard Graduate School of Business Administration的工商管理硕士学位，是一名Baker学者，以及The Rockefeller University的神经系统科学/生物化学博士学位。
- Jessica Hopfield,has served on Board of Directors since July 2015, serving as Lead Independent Director from August 2016 through December 2018. She is the former Chair of the Joslin Diabetes Center.She is a strategic advisor and investor in healthcare and technology firms seeking to commercialize innovative intellectual property. From 1995 to 2009, Dr. Hopfield was a Partner at McKinsey & Company in their global pharmaceuticals and medical devices practice and she served clients across the pharmaceutical, biotech, medical device and consumer industries with a focus on strategy, R&D management and marketing. She also previously held management positions at Merck Sharp & Dohme Corp. in clinical development, outcomes research, and marketing. Dr. Hopfield earned a Bachelor of Science from Yale College, an MBA from the Harvard Graduate School of Business Administration as a Baker Scholar, and a Doctor of Philosophy in Neuroscience/Biochemistry from The Rockefeller University.
- Andrew Hirsch
-
暂无中文简介
Andrew Hirsch has served as a member of our board of directors since May 2017. Mr. Hirsch is currently the Chief Financial Officer and Head of Corporate Development of Agios Pharmaceuticals, Inc., a pharmaceutical company, or Agios. Mr. Hirsch has served as Agios' Chief Financial Officer since September 2016 and as its Head of Corporate Development since March 2018. Prior to being named president and chief executive officer at BIND, Mr. Hirsch held several other leadership positions at BIND, including chief operating officer from February 2014 to March 2015 and chief financial officer from July 2012 to March 2015. In May 2016 BIND Therapeutics filed a voluntary petition for bankruptcy under Chapter 11 of the United States Bankruptcy Code with the United States Bankruptcy Court. Prior to joining BIND, Mr. Hirsch was chief financial officer at Avila Therapeutics, Inc., a biotechnology company, or Avila, from June 2011 until its acquisition by Celgene Corporation, a public biopharmaceutical company, or Celgene, in March 2012. From 2002 to 2011 Mr. Hirsch held roles of increasing responsibility at Biogen, Inc. formerly Biogen Idec, Inc., a biotechnology company, or Biogen, including vice president of Corporate Strategy and M&A and program executive for the Tecfidera development team. He holds an M.B.A. from the Tuck School at Dartmouth College and a B.A. in Economics from the University of Pennsylvania. -
暂无中文简介
- Andrew Hirsch has served as a member of our board of directors since May 2017. Mr. Hirsch is currently the Chief Financial Officer and Head of Corporate Development of Agios Pharmaceuticals, Inc., a pharmaceutical company, or Agios. Mr. Hirsch has served as Agios' Chief Financial Officer since September 2016 and as its Head of Corporate Development since March 2018. Prior to being named president and chief executive officer at BIND, Mr. Hirsch held several other leadership positions at BIND, including chief operating officer from February 2014 to March 2015 and chief financial officer from July 2012 to March 2015. In May 2016 BIND Therapeutics filed a voluntary petition for bankruptcy under Chapter 11 of the United States Bankruptcy Code with the United States Bankruptcy Court. Prior to joining BIND, Mr. Hirsch was chief financial officer at Avila Therapeutics, Inc., a biotechnology company, or Avila, from June 2011 until its acquisition by Celgene Corporation, a public biopharmaceutical company, or Celgene, in March 2012. From 2002 to 2011 Mr. Hirsch held roles of increasing responsibility at Biogen, Inc. formerly Biogen Idec, Inc., a biotechnology company, or Biogen, including vice president of Corporate Strategy and M&A and program executive for the Tecfidera development team. He holds an M.B.A. from the Tuck School at Dartmouth College and a B.A. in Economics from the University of Pennsylvania.
- James Mullen
-
James Mullen自2018年3月以来一直担任我们的董事会主席。Mullen先生曾于2011年3月至2017年8月被Thermo Fisher Scientific，Inc.收购期间担任制药合同开发和制造组织PatheonN.V.（Patheon）的首席执行官兼董事。加入Patheon之前，Mullen从2000年6月到2010年6月担任Biogen（世界上最大的生物技术公司之一）总裁和首席执行官。Mullen先生在成为首席执行官之前曾在Biogen担任过多个运营职位，包括国际Vice President和Vice President运营部的首席运营官。加入Biogen之前，Mullen曾在SmithKline Beecham（现为GlaxoSmithKline plc）担任多个制造和工程职位。Mullen先生自2017年8月起担任私营生物制药商业化公司Vicarius Pharma AG的董事会执行主席，并自2017年9月起担任公共医疗器械公司Insulet Corporation（Insulet）的董事会成员。Mullen先生曾于2003年至2015年4月担任珀金埃尔默公司董事会成员，该公司是诊断、研究、环境以及工业和实验室服务市场的公共技术和服务提供商。他此前也曾担任Biotechnology Innovation Organization的主席。Mullen先生在伦斯勒理工学院（Rensselaer Polytechnic Institute）获得化学工程学士学位，并在维拉诺瓦大学（Villanova University）获得工商管理硕士学位。
James Mullen has served as chairman of our board of directors since March 2018. Mr. Mullen previously served as Chief Executive Officer and a director of Patheon N.V., a pharmaceutical contract development and manufacturing organization, or Patheon, from March 2011 until its acquisition by Thermo Fisher Scientific, Inc. in August 2017. Prior to joining Patheon, from June 2000 to June 2010 Mr. Mullen served as the President and Chief Executive Officer of Biogen, one of the world's largest biotechnology companies. Mr. Mullen held various operating positions at Biogen prior to becoming Chief Executive Officer, including Chief Operating Officer, Vice President, International, and Vice President, Operations. Prior to joining Biogen, Mr. Mullen held several manufacturing and engineering positions at SmithKline Beecham now GlaxoSmithKline plc. Mr. Mullen has served as the executive chairman of the board of Vicarius Pharma AG, a private bio-pharmaceutical commercialization company, since August 2017 and on the board of directors of Insulet Corporation, a public medical device company, or Insulet, since September 2017. Mr. Mullen previously served on the board of directors of PerkinElmer, Inc., a public technology and service provider for diagnostics, research, environmental and industrial and laboratory services markets, from 2003 to April 2015. He also previously served as Chairman of the Biotechnology Innovation Organization. Mr. Mullen received a B.S. in Chemical Engineering from Rensselaer Polytechnic Institute and an M.B.A. from Villanova University. - James Mullen自2018年3月以来一直担任我们的董事会主席。Mullen先生曾于2011年3月至2017年8月被Thermo Fisher Scientific，Inc.收购期间担任制药合同开发和制造组织PatheonN.V.（Patheon）的首席执行官兼董事。加入Patheon之前，Mullen从2000年6月到2010年6月担任Biogen（世界上最大的生物技术公司之一）总裁和首席执行官。Mullen先生在成为首席执行官之前曾在Biogen担任过多个运营职位，包括国际Vice President和Vice President运营部的首席运营官。加入Biogen之前，Mullen曾在SmithKline Beecham（现为GlaxoSmithKline plc）担任多个制造和工程职位。Mullen先生自2017年8月起担任私营生物制药商业化公司Vicarius Pharma AG的董事会执行主席，并自2017年9月起担任公共医疗器械公司Insulet Corporation（Insulet）的董事会成员。Mullen先生曾于2003年至2015年4月担任珀金埃尔默公司董事会成员，该公司是诊断、研究、环境以及工业和实验室服务市场的公共技术和服务提供商。他此前也曾担任Biotechnology Innovation Organization的主席。Mullen先生在伦斯勒理工学院（Rensselaer Polytechnic Institute）获得化学工程学士学位，并在维拉诺瓦大学（Villanova University）获得工商管理硕士学位。
- James Mullen has served as chairman of our board of directors since March 2018. Mr. Mullen previously served as Chief Executive Officer and a director of Patheon N.V., a pharmaceutical contract development and manufacturing organization, or Patheon, from March 2011 until its acquisition by Thermo Fisher Scientific, Inc. in August 2017. Prior to joining Patheon, from June 2000 to June 2010 Mr. Mullen served as the President and Chief Executive Officer of Biogen, one of the world's largest biotechnology companies. Mr. Mullen held various operating positions at Biogen prior to becoming Chief Executive Officer, including Chief Operating Officer, Vice President, International, and Vice President, Operations. Prior to joining Biogen, Mr. Mullen held several manufacturing and engineering positions at SmithKline Beecham now GlaxoSmithKline plc. Mr. Mullen has served as the executive chairman of the board of Vicarius Pharma AG, a private bio-pharmaceutical commercialization company, since August 2017 and on the board of directors of Insulet Corporation, a public medical device company, or Insulet, since September 2017. Mr. Mullen previously served on the board of directors of PerkinElmer, Inc., a public technology and service provider for diagnostics, research, environmental and industrial and laboratory services markets, from 2003 to April 2015. He also previously served as Chairman of the Biotechnology Innovation Organization. Mr. Mullen received a B.S. in Chemical Engineering from Rensselaer Polytechnic Institute and an M.B.A. from Villanova University.
- Jessica Hopfield
-
暂无中文简介
Jessica Hopfield, Ph.D., joined our board of directors in February 2018. Dr. Hopfield has served on the Board of Directors of Insulet since July 2015 and as its Lead Independent Director since August 2016. In October 2015 Dr. Hopfield was appointed, and currently serves, as Chairperson of the Board of Trustees of the Joslin Diabetes Center. From 2013 to October 2015 Dr. Hopfield served as the Vice Chair of the Board of Trustees of the Joslin Diabetes Center. Since 2010 Dr. Hopfield has been the principal at J Hopfield Consulting providing guidance and executive coaching to start-up technology firms. From 1995 to 2009 Dr. Hopfield was a Partner of McKinsey & Company in their global pharmaceuticals and medical devices practice and she served clients across pharmaceutical, biotechnology, medical device and consumer industries with a focus on strategy, R&D management, and marketing. Dr. Hopfield also previously held management positions at Merck Sharp & Dohme Corp. in clinical development, outcomes research, and marketing, and served on the board of rEVO Biologics, a private company. Dr. Hopfield earned a B.S. from Yale College, an M.B.A. from Harvard Graduate School of Business Administration as a Baker Scholar, and a Ph.D. in Neuroscience/Biochemistry from The Rockefeller University. -
暂无中文简介
- Jessica Hopfield, Ph.D., joined our board of directors in February 2018. Dr. Hopfield has served on the Board of Directors of Insulet since July 2015 and as its Lead Independent Director since August 2016. In October 2015 Dr. Hopfield was appointed, and currently serves, as Chairperson of the Board of Trustees of the Joslin Diabetes Center. From 2013 to October 2015 Dr. Hopfield served as the Vice Chair of the Board of Trustees of the Joslin Diabetes Center. Since 2010 Dr. Hopfield has been the principal at J Hopfield Consulting providing guidance and executive coaching to start-up technology firms. From 1995 to 2009 Dr. Hopfield was a Partner of McKinsey & Company in their global pharmaceuticals and medical devices practice and she served clients across pharmaceutical, biotechnology, medical device and consumer industries with a focus on strategy, R&D management, and marketing. Dr. Hopfield also previously held management positions at Merck Sharp & Dohme Corp. in clinical development, outcomes research, and marketing, and served on the board of rEVO Biologics, a private company. Dr. Hopfield earned a B.S. from Yale College, an M.B.A. from Harvard Graduate School of Business Administration as a Baker Scholar, and a Ph.D. in Neuroscience/Biochemistry from The Rockefeller University.
- Akshay K. Vaishnaw
-
Akshay K. Vaishnaw，自2012年6月，他是公司的高级副总裁兼首席医疗官，曾担任公司执行副总裁兼首席医疗官自2011年6月至2012年6月。他担任公司临床研究的高级副总裁从2008年12月至2011年6月，在此之前，2006年1月起担任公司临床研究副总裁。1998年12月至2005年12 月他在Biogen Idec公司（公司前身为生物遗传公司，一家生物制药公司）担任过多个职位。 他是英国皇家医师学院的成员。
Akshay K. Vaishnaw, M.D., Ph.D., has served as a member of our board of directors since July 2016. Dr. Vaishnaw has served as the President, Research and Development of Alnylam Pharmaceuticals, Inc., or Alnylam, which develops RNA-based therapies, since March 2018. Prior to that, Dr. Vaishnaw held a variety of positions at Alnylam, including Executive Vice President, Research and Development from December 2014 until March 2018 Chief Medical Officer from June 2011 until December 2016 Executive Vice President from June 2012 to December 2014 Senior Vice President from June 2011 to June 2012 Senior Vice President, Clinical Research from December 2008 to June 2011 and Vice President, Clinical Research from 2006 to 2008. Since December 2014 Dr. Vaishnaw has served as a director of Visterra, Inc., a private biopharmaceutical company focused on antibody-based therapies. From 1998 to 2005 Dr. Vaishnaw held various positions at Biogen. Dr. Vaishnaw is a Fellow of the Royal College of Physicians, United Kingdom. He received his M.D. from University of Wales College of Medicine and his Ph.D. from the University of London. - Akshay K. Vaishnaw，自2012年6月，他是公司的高级副总裁兼首席医疗官，曾担任公司执行副总裁兼首席医疗官自2011年6月至2012年6月。他担任公司临床研究的高级副总裁从2008年12月至2011年6月，在此之前，2006年1月起担任公司临床研究副总裁。1998年12月至2005年12 月他在Biogen Idec公司（公司前身为生物遗传公司，一家生物制药公司）担任过多个职位。 他是英国皇家医师学院的成员。
- Akshay K. Vaishnaw, M.D., Ph.D., has served as a member of our board of directors since July 2016. Dr. Vaishnaw has served as the President, Research and Development of Alnylam Pharmaceuticals, Inc., or Alnylam, which develops RNA-based therapies, since March 2018. Prior to that, Dr. Vaishnaw held a variety of positions at Alnylam, including Executive Vice President, Research and Development from December 2014 until March 2018 Chief Medical Officer from June 2011 until December 2016 Executive Vice President from June 2012 to December 2014 Senior Vice President from June 2011 to June 2012 Senior Vice President, Clinical Research from December 2008 to June 2011 and Vice President, Clinical Research from 2006 to 2008. Since December 2014 Dr. Vaishnaw has served as a director of Visterra, Inc., a private biopharmaceutical company focused on antibody-based therapies. From 1998 to 2005 Dr. Vaishnaw held various positions at Biogen. Dr. Vaishnaw is a Fellow of the Royal College of Physicians, United Kingdom. He received his M.D. from University of Wales College of Medicine and his Ph.D. from the University of London.
- Andrew Hirsch
-
Andrew Hirsch，2014年2月15日开始担任首席运营官。2012年7月起，他一直是我们的首席财务官。2011年6月至2012年5月，他是Avila Therapeutics公司（一家生物技术公司）财务副总裁和首席财务官，直到被Celgene公司收购。2002年到2011年，他在Biogen Idec公司（一个生物技术公司）担任过各种职位，包括2010年到2011年担任公司战略和并购副总裁。2007年到2010年，他在Biogen Idec的金融组织担任不同职位，包括领导业务规划和投资者关系的功能。此外，他还担任神经病学项目执行者，主要为BG-12 Biogen Idec的开发团队，现在销售Tecfidera,Avonex和Tysabri项目。他持有达特茅斯学院塔克商学院mba，宾夕法尼亚大学的经济学学士学位。
Andrew Hirsch has served as our President and a member of our Board of Directors since September 2020 and has been elected to serve as our Chief Executive Officer effective as of October 2 2020. Since May 2017 Mr. Hirsch has served on the board of directors of Editas Medicine, Inc. Nasdaq: EDIT, a pharmaceutical company, and also serves as the chair of its audit committee. From September 2016 to September 2020 Mr. Hirsch served as Chief Financial Officer at Agios Pharmaceuticals, Inc., a public pharmaceutical company, including as head of corporate development beginning March 2018. From March 2015 until August 2016 he served as President and Chief Executive Officer of BIND Therapeutics, Inc., or BIND, a biotechnology company. Prior to being named President and Chief Executive Officer, Mr. Hirsch held several other leadership positions at BIND, including Chief Operating Officer from February 2014 to March 2015 and Chief Financial Officer from July 2012 to March 2015. Prior to joining BIND, Mr. Hirsch was Chief Financial Officer at Avila Therapeutics, Inc., a biotechnology company, from June 2011 until its acquisition by Celgene Corporation in March 2012. From 2002 to 2011 Mr. Hirsch held roles of increasing responsibility at Biogen Inc., including Vice President of Corporate Strategy and M&A and program executive for the Tecfidera development team. He holds an M.B.A. from the Tuck School at Dartmouth College and a B.A. in Economics from the University of Pennsylvania. - Andrew Hirsch，2014年2月15日开始担任首席运营官。2012年7月起，他一直是我们的首席财务官。2011年6月至2012年5月，他是Avila Therapeutics公司（一家生物技术公司）财务副总裁和首席财务官，直到被Celgene公司收购。2002年到2011年，他在Biogen Idec公司（一个生物技术公司）担任过各种职位，包括2010年到2011年担任公司战略和并购副总裁。2007年到2010年，他在Biogen Idec的金融组织担任不同职位，包括领导业务规划和投资者关系的功能。此外，他还担任神经病学项目执行者，主要为BG-12 Biogen Idec的开发团队，现在销售Tecfidera,Avonex和Tysabri项目。他持有达特茅斯学院塔克商学院mba，宾夕法尼亚大学的经济学学士学位。
- Andrew Hirsch has served as our President and a member of our Board of Directors since September 2020 and has been elected to serve as our Chief Executive Officer effective as of October 2 2020. Since May 2017 Mr. Hirsch has served on the board of directors of Editas Medicine, Inc. Nasdaq: EDIT, a pharmaceutical company, and also serves as the chair of its audit committee. From September 2016 to September 2020 Mr. Hirsch served as Chief Financial Officer at Agios Pharmaceuticals, Inc., a public pharmaceutical company, including as head of corporate development beginning March 2018. From March 2015 until August 2016 he served as President and Chief Executive Officer of BIND Therapeutics, Inc., or BIND, a biotechnology company. Prior to being named President and Chief Executive Officer, Mr. Hirsch held several other leadership positions at BIND, including Chief Operating Officer from February 2014 to March 2015 and Chief Financial Officer from July 2012 to March 2015. Prior to joining BIND, Mr. Hirsch was Chief Financial Officer at Avila Therapeutics, Inc., a biotechnology company, from June 2011 until its acquisition by Celgene Corporation in March 2012. From 2002 to 2011 Mr. Hirsch held roles of increasing responsibility at Biogen Inc., including Vice President of Corporate Strategy and M&A and program executive for the Tecfidera development team. He holds an M.B.A. from the Tuck School at Dartmouth College and a B.A. in Economics from the University of Pennsylvania.
- Katrine Bosley
-
Katrine Bosley，自2013年3月起，她一直是我们的董事会成员；自2013年8月起，担任我们的董事长。目前，她是 The Broad Institute的常驻企业家。自2009年5月至2012年3月Avila被Celgene Corporation收购，她担任Avila Therapeutics Inc或者说Avila，的首席执行官。在加入Avila之前，她是Adnexus的副总裁，负责战略运营部，这是一个布里斯托尔梅尔斯的公司；在那之前，担任Adnexus Therapeutics Inc.， 或者Adnexus的业务开发部的副总裁。她离开Biogen Idec （在该公司，她在美国和欧洲的业务开发、商业运营和证券投资组合战略方面担任过许多职务，并负责Tysabri那她珠单抗在一些其他交易方面的许可）加入Adnexus。在此之前，1993年至1995年，她是风险公司 Highland Capital Partners医疗保健团队的成员。除了担任我们公司的董事之外，她目前还担任Galapagos NV 和 Coco Therapeutics Ltd.的董事。她毕业于Cornell University，取得了生物学文学士学位。
Katrine Bosley has served as a member of our board of directors since 2013. Ms. Bosley served as the President, Chief Executive Officer and member of the board of directors of Editas Medicine, Inc. from June 2014 to March 2019. Prior to joining Editas, Ms. Bosley was the Entrepreneur-in-Residence at The Broad Institute from 2013 to 2014. From 2009 to 2012 Ms. Bosley was President, Chief Executive Officer and member of the board of directors of Avila Therapeutics, Inc., which was acquired by Celgene Corporation in 2012. Ms. Bosley served as President, Celgene Avilomics Research at Celgene in 2012. Prior to her time at Avila Therapeutics, Ms. Bosley was Vice President, Strategic Operations at Adnexus, a Bristol-Myers Squibb R&D Company, and was Vice President, Business Development at Adnexus Therapeutics, Inc. before that. Ms. Bosley joined Adnexus Therapeutics from Biogen Idec, Inc. where she had roles in business development, commercial operations and portfolio strategy in the United States and Europe. Ms. Bosley graduated from Cornell University with a B.A. in Biology. Ms. Bosley currently serves on the boards of Genocea Biosciences, Inc., and of the Massachusetts Eye and Ear Institute. Ms. Bosley also serves as chairman of the board of Arrakis Therapeutics. - Katrine Bosley，自2013年3月起，她一直是我们的董事会成员；自2013年8月起，担任我们的董事长。目前，她是 The Broad Institute的常驻企业家。自2009年5月至2012年3月Avila被Celgene Corporation收购，她担任Avila Therapeutics Inc或者说Avila，的首席执行官。在加入Avila之前，她是Adnexus的副总裁，负责战略运营部，这是一个布里斯托尔梅尔斯的公司；在那之前，担任Adnexus Therapeutics Inc.， 或者Adnexus的业务开发部的副总裁。她离开Biogen Idec （在该公司，她在美国和欧洲的业务开发、商业运营和证券投资组合战略方面担任过许多职务，并负责Tysabri那她珠单抗在一些其他交易方面的许可）加入Adnexus。在此之前，1993年至1995年，她是风险公司 Highland Capital Partners医疗保健团队的成员。除了担任我们公司的董事之外，她目前还担任Galapagos NV 和 Coco Therapeutics Ltd.的董事。她毕业于Cornell University，取得了生物学文学士学位。
- Katrine Bosley has served as a member of our board of directors since 2013. Ms. Bosley served as the President, Chief Executive Officer and member of the board of directors of Editas Medicine, Inc. from June 2014 to March 2019. Prior to joining Editas, Ms. Bosley was the Entrepreneur-in-Residence at The Broad Institute from 2013 to 2014. From 2009 to 2012 Ms. Bosley was President, Chief Executive Officer and member of the board of directors of Avila Therapeutics, Inc., which was acquired by Celgene Corporation in 2012. Ms. Bosley served as President, Celgene Avilomics Research at Celgene in 2012. Prior to her time at Avila Therapeutics, Ms. Bosley was Vice President, Strategic Operations at Adnexus, a Bristol-Myers Squibb R&D Company, and was Vice President, Business Development at Adnexus Therapeutics, Inc. before that. Ms. Bosley joined Adnexus Therapeutics from Biogen Idec, Inc. where she had roles in business development, commercial operations and portfolio strategy in the United States and Europe. Ms. Bosley graduated from Cornell University with a B.A. in Biology. Ms. Bosley currently serves on the boards of Genocea Biosciences, Inc., and of the Massachusetts Eye and Ear Institute. Ms. Bosley also serves as chairman of the board of Arrakis Therapeutics.
高管简历
中英对照 | 中文 | 英文- Andrew A. F. Hack
Andrew A. F. Hack自2015年7月起担任公司首席财务官。加入Andrew A. F. Hack之前，Hack从2011年5月到2015年6月担任Millennium Management LLC（一家机构资产管理公司）投资组合经理，运营专注于生物技术、制药和医疗设备公司的医疗基金。加入Millennium Management之前，Hack从2008年12月到2011年5月担任HealthCor Management, L.P.（一家注册投资咨询商）医疗分析师。加入HealthCor之前，Hack担任对冲基金Carlyle'Blue Wave Partners医疗分析师和MPM BioEquities Fund（附属于MPM Capital的对冲基金）主要负责人。Hack在生物技术行业的投资银行Banc of America Securities LLC 以及 Rodman & Renshaw, LLC.开始自己的职业生涯。Hack联合创立了Reify Corporation（一家生命科学工具和药物发现公司）。Hack持有the University of Chicago生物学文学学士学位；他还获得了硕士和博士学位。
Andrew A. F. Hack has served as a member of Nuvalent, Inc.'s board of directors since April 2021. Since March 2019 Dr. Hack has served as a Managing Director of Bain Capital Life Sciences, a private equity fund that invests in biopharmaceutical, specialty pharmaceutical, medical device, diagnostics, and enabling life science technology companies globally, and since August 2020 has served as Chief Financial Officer and a member of the board of directors of BCLS Acquisition Corp., a special purpose acquisition company sponsored by an affiliate of Bain Capital Life Sciences. From July 2015 to March 2019 he was the Chief Financial Officer of Editas Medicine NASDAQ: EDIT. Previously, Dr. Hack served as a portfolio manager at Millennium Management from May 2011 to June 2015 where he ran a healthcare hedge fund focused on biotechnology, pharmaceutical and medical device companies. Earlier in his investment career, he was a securities analyst at a number of healthcare-focused hedge funds and investment banks in New York. Prior to this, he was Director of Life Sciences at Reify Corporation, a life science tools and drug discovery company. Dr. Hack currently serves on the boards of directors of BCLS Acquisition Corporation (NASDAQ: BLSA), Dynavax Technologies Corporation (NASDAQ: DVAX), and Mersana Therapeutics, Inc. (NASDAQ: MRSN), which are portfolio companies of Bain Capital Life Sciences. He previously served on the boards of directors of Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) and Allena Pharmaceuticals (NASDAQ: ALNA), which are also portfolio companies of Bain Capital Life Sciences. Dr. Hack received an M.D. and Ph.D. in Molecular Genetics and Cell biology, as well as an A.B. in Biology with Special Honors from the University of Chicago.- Andrew A. F. Hack自2015年7月起担任公司首席财务官。加入Andrew A. F. Hack之前，Hack从2011年5月到2015年6月担任Millennium Management LLC（一家机构资产管理公司）投资组合经理，运营专注于生物技术、制药和医疗设备公司的医疗基金。加入Millennium Management之前，Hack从2008年12月到2011年5月担任HealthCor Management, L.P.（一家注册投资咨询商）医疗分析师。加入HealthCor之前，Hack担任对冲基金Carlyle'Blue Wave Partners医疗分析师和MPM BioEquities Fund（附属于MPM Capital的对冲基金）主要负责人。Hack在生物技术行业的投资银行Banc of America Securities LLC 以及 Rodman & Renshaw, LLC.开始自己的职业生涯。Hack联合创立了Reify Corporation（一家生命科学工具和药物发现公司）。Hack持有the University of Chicago生物学文学学士学位；他还获得了硕士和博士学位。
- Andrew A. F. Hack has served as a member of Nuvalent, Inc.'s board of directors since April 2021. Since March 2019 Dr. Hack has served as a Managing Director of Bain Capital Life Sciences, a private equity fund that invests in biopharmaceutical, specialty pharmaceutical, medical device, diagnostics, and enabling life science technology companies globally, and since August 2020 has served as Chief Financial Officer and a member of the board of directors of BCLS Acquisition Corp., a special purpose acquisition company sponsored by an affiliate of Bain Capital Life Sciences. From July 2015 to March 2019 he was the Chief Financial Officer of Editas Medicine NASDAQ: EDIT. Previously, Dr. Hack served as a portfolio manager at Millennium Management from May 2011 to June 2015 where he ran a healthcare hedge fund focused on biotechnology, pharmaceutical and medical device companies. Earlier in his investment career, he was a securities analyst at a number of healthcare-focused hedge funds and investment banks in New York. Prior to this, he was Director of Life Sciences at Reify Corporation, a life science tools and drug discovery company. Dr. Hack currently serves on the boards of directors of BCLS Acquisition Corporation (NASDAQ: BLSA), Dynavax Technologies Corporation (NASDAQ: DVAX), and Mersana Therapeutics, Inc. (NASDAQ: MRSN), which are portfolio companies of Bain Capital Life Sciences. He previously served on the boards of directors of Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) and Allena Pharmaceuticals (NASDAQ: ALNA), which are also portfolio companies of Bain Capital Life Sciences. Dr. Hack received an M.D. and Ph.D. in Molecular Genetics and Cell biology, as well as an A.B. in Biology with Special Honors from the University of Chicago.
- Charles Albright
Charles Albright博士自2016年8月起担任我们的首席科学官。在加入Editas之前，Albright博士曾于2004年1月至2016年8月在生物制药公司百时美施贵宝公司担任各种职务，最近担任Vice President，基因定义疾病和基因组学。Albright博士在麻省理工学院（Massachusetts Institute of Technology）获得化学工程学士学位和生物学博士学位。
Charles Albright, Ph.D., has served as our Chief Scientific Officer since August 2016. Prior to joining Editas, Dr. Albright served in a variety of roles at Bristol-Myers Squibb Company, a biopharmaceutical company, from January 2004 to August 2016 serving most recently as the Vice President, Genetically Defined Diseases and Genomics. Dr. Albright received his B.S. in chemical engineering and a Ph.D. in biology from the Massachusetts Institute of Technology.- Charles Albright博士自2016年8月起担任我们的首席科学官。在加入Editas之前，Albright博士曾于2004年1月至2016年8月在生物制药公司百时美施贵宝公司担任各种职务，最近担任Vice President，基因定义疾病和基因组学。Albright博士在麻省理工学院（Massachusetts Institute of Technology）获得化学工程学士学位和生物学博士学位。
- Charles Albright, Ph.D., has served as our Chief Scientific Officer since August 2016. Prior to joining Editas, Dr. Albright served in a variety of roles at Bristol-Myers Squibb Company, a biopharmaceutical company, from January 2004 to August 2016 serving most recently as the Vice President, Genetically Defined Diseases and Genomics. Dr. Albright received his B.S. in chemical engineering and a Ph.D. in biology from the Massachusetts Institute of Technology.
- Gerald Cox
Gerald Cox，医学博士，博士，自2016年10月起担任我们的首席医疗官。在加入Editas之前，Cox博士于2000年8月至2016年8月在生物技术公司Sanofi Genzyme担任多个职位，最近担任罕见疾病临床开发Vice President。Cox博士从1994年7月开始担任波士顿儿童医院（Boston Children’s Hospital）的遗传学工作人员，并从1994年8月开始担任哈佛医学院（Harvard Medical School）的儿科讲师。Cox博士在哈佛学院（Harvard College）获得生物学学士学位，并在加州大学圣地亚哥分校（University of California at San Diego）获得医学博士学位和博士学位。
Gerald Cox, M.D., Ph.D., has served as our Chief Medical Officer since October 2016. Prior to joining Editas, Dr. Cox served in a variety of roles at Sanofi Genzyme, a biotechnology company, from August 2000 to August 2016 serving most recently as the Vice President of Clinical Development for Rare Diseases. Since July 1994 Dr. Cox has served as a Staff Physician in Genetics at Boston Children's Hospital and, since August 1994 as an Instructor in Pediatrics at Harvard Medical School. Dr. Cox received his B.A. in biology from Harvard College and his M.D. and Ph.D. from the University of California at San Diego.- Gerald Cox，医学博士，博士，自2016年10月起担任我们的首席医疗官。在加入Editas之前，Cox博士于2000年8月至2016年8月在生物技术公司Sanofi Genzyme担任多个职位，最近担任罕见疾病临床开发Vice President。Cox博士从1994年7月开始担任波士顿儿童医院（Boston Children’s Hospital）的遗传学工作人员，并从1994年8月开始担任哈佛医学院（Harvard Medical School）的儿科讲师。Cox博士在哈佛学院（Harvard College）获得生物学学士学位，并在加州大学圣地亚哥分校（University of California at San Diego）获得医学博士学位和博士学位。
- Gerald Cox, M.D., Ph.D., has served as our Chief Medical Officer since October 2016. Prior to joining Editas, Dr. Cox served in a variety of roles at Sanofi Genzyme, a biotechnology company, from August 2000 to August 2016 serving most recently as the Vice President of Clinical Development for Rare Diseases. Since July 1994 Dr. Cox has served as a Staff Physician in Genetics at Boston Children's Hospital and, since August 1994 as an Instructor in Pediatrics at Harvard Medical School. Dr. Cox received his B.A. in biology from Harvard College and his M.D. and Ph.D. from the University of California at San Diego.
- Katrine Bosley
Katrine Bosley，自2013年3月起，她一直是我们的董事会成员；自2013年8月起，担任我们的董事长。目前，她是 The Broad Institute的常驻企业家。自2009年5月至2012年3月Avila被Celgene Corporation收购，她担任Avila Therapeutics Inc或者说Avila，的首席执行官。在加入Avila之前，她是Adnexus的副总裁，负责战略运营部，这是一个布里斯托尔梅尔斯的公司；在那之前，担任Adnexus Therapeutics Inc.， 或者Adnexus的业务开发部的副总裁。她离开Biogen Idec （在该公司，她在美国和欧洲的业务开发、商业运营和证券投资组合战略方面担任过许多职务，并负责Tysabri那她珠单抗在一些其他交易方面的许可）加入Adnexus。在此之前，1993年至1995年，她是风险公司 Highland Capital Partners医疗保健团队的成员。除了担任我们公司的董事之外，她目前还担任Galapagos NV 和 Coco Therapeutics Ltd.的董事。她毕业于Cornell University，取得了生物学文学士学位。
Katrine Bosley has served as a member of our board of directors since 2013. Ms. Bosley served as the President, Chief Executive Officer and member of the board of directors of Editas Medicine, Inc. from June 2014 to March 2019. Prior to joining Editas, Ms. Bosley was the Entrepreneur-in-Residence at The Broad Institute from 2013 to 2014. From 2009 to 2012 Ms. Bosley was President, Chief Executive Officer and member of the board of directors of Avila Therapeutics, Inc., which was acquired by Celgene Corporation in 2012. Ms. Bosley served as President, Celgene Avilomics Research at Celgene in 2012. Prior to her time at Avila Therapeutics, Ms. Bosley was Vice President, Strategic Operations at Adnexus, a Bristol-Myers Squibb R&D Company, and was Vice President, Business Development at Adnexus Therapeutics, Inc. before that. Ms. Bosley joined Adnexus Therapeutics from Biogen Idec, Inc. where she had roles in business development, commercial operations and portfolio strategy in the United States and Europe. Ms. Bosley graduated from Cornell University with a B.A. in Biology. Ms. Bosley currently serves on the boards of Genocea Biosciences, Inc., and of the Massachusetts Eye and Ear Institute. Ms. Bosley also serves as chairman of the board of Arrakis Therapeutics.- Katrine Bosley，自2013年3月起，她一直是我们的董事会成员；自2013年8月起，担任我们的董事长。目前，她是 The Broad Institute的常驻企业家。自2009年5月至2012年3月Avila被Celgene Corporation收购，她担任Avila Therapeutics Inc或者说Avila，的首席执行官。在加入Avila之前，她是Adnexus的副总裁，负责战略运营部，这是一个布里斯托尔梅尔斯的公司；在那之前，担任Adnexus Therapeutics Inc.， 或者Adnexus的业务开发部的副总裁。她离开Biogen Idec （在该公司，她在美国和欧洲的业务开发、商业运营和证券投资组合战略方面担任过许多职务，并负责Tysabri那她珠单抗在一些其他交易方面的许可）加入Adnexus。在此之前，1993年至1995年，她是风险公司 Highland Capital Partners医疗保健团队的成员。除了担任我们公司的董事之外，她目前还担任Galapagos NV 和 Coco Therapeutics Ltd.的董事。她毕业于Cornell University，取得了生物学文学士学位。
- Katrine Bosley has served as a member of our board of directors since 2013. Ms. Bosley served as the President, Chief Executive Officer and member of the board of directors of Editas Medicine, Inc. from June 2014 to March 2019. Prior to joining Editas, Ms. Bosley was the Entrepreneur-in-Residence at The Broad Institute from 2013 to 2014. From 2009 to 2012 Ms. Bosley was President, Chief Executive Officer and member of the board of directors of Avila Therapeutics, Inc., which was acquired by Celgene Corporation in 2012. Ms. Bosley served as President, Celgene Avilomics Research at Celgene in 2012. Prior to her time at Avila Therapeutics, Ms. Bosley was Vice President, Strategic Operations at Adnexus, a Bristol-Myers Squibb R&D Company, and was Vice President, Business Development at Adnexus Therapeutics, Inc. before that. Ms. Bosley joined Adnexus Therapeutics from Biogen Idec, Inc. where she had roles in business development, commercial operations and portfolio strategy in the United States and Europe. Ms. Bosley graduated from Cornell University with a B.A. in Biology. Ms. Bosley currently serves on the boards of Genocea Biosciences, Inc., and of the Massachusetts Eye and Ear Institute. Ms. Bosley also serves as chairman of the board of Arrakis Therapeutics.